A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.

Reassuring for GIP agonism. This seems to meet previous FDA CV safety standard ahead of CV outcomes trial. #tirzepatide https://t.co/cBo21QZmiy https://t.co/SRvuoPegE6

Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are still alive six years later.

YouTube video by Ann Marie Navar

Recent research suggests that more people should be screened for a protein called apoB. A growing number of doctors agree.

Nature Reviews Cardiology, Published online: 23 January 2026; doi:10.1038/s41569-026-01249-zIn this Review, Galli and colleagues discuss the mechanisms and associated biomarkers of traditional and emerging factors responsible for the residual risk of recurrent adverse cardiovascular events in patients with coronary artery disease, with a focus on new pathophysiological insights and the therapeutic implications.

NephJC short on an empagliflozin meta-analysis

This study suggests that ApoB is a more accurate marker for cardiovascular risk than LDL-P when discordant, as marked by ApoB levels in excess of LDL-P. Notably, risk was already elevated at as little...

Cost-effectiveness of Lipoprotein(a) [Lp(a)] testing is not established. We aimed to evaluate the cost-effectiveness of Lp(a) testing in the cardiovas…

Colchicine: Evidence to Treat or Equipoise?

El investigador canadiense acaba de recibir el Premio Fronteras del Conocimiento por su papel en los fármacos antiobesidad, aunque es conservador sobre su uso

Enlicitide demonstrated statistically significant and clinically meaningful reductions in LDL-C in both Phase 3 CORALreef HeFH and CORALreef AddOn trials Enlicitide, a novel macrocyclic peptide, has t...

Predicting cardiovascular risk in young adults remains challenging. The newly developed PREVENT equations offers several advantages for short and long-term cardiovascular risk prediction. To determine...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di...

The debate over whether to agonize or antagonize GIPR signalling has divided the obesity drug design field. Studies from Gutgesell et al. and Liu et al. represent important first steps towards disenta...